93 related articles for article (PubMed ID: 2232966)
21. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer.
Meehan KR; Arun B; Gehan EA; Berberian B; Sulica V; Areman EM; Mazumder A; Lippman ME
Bone Marrow Transplant; 1999 Apr; 23(7):667-73. PubMed ID: 10218842
[TBL] [Abstract][Full Text] [Related]
23. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
25. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
26. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
27. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
28. [Immunologic study on patients with head and neck cancer treated with thymopentin associated with surgery, chemotherapy and radiotherapy].
Denaro A; Stivala F; Mazzarino MC
Acta Otorhinolaryngol Ital; 1994; 14(6):611-25. PubMed ID: 7740961
[TBL] [Abstract][Full Text] [Related]
29. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
30. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
31. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer.
Coleman S; Clayton A; Mason MD; Jasani B; Adams M; Tabi Z
Cancer Res; 2005 Aug; 65(15):7000-6. PubMed ID: 16061686
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy.
Gebbia V; Valenza R; Testa A; Cannata G; Borsellino N; Gebbia N
Anticancer Res; 1994; 14(2B):731-4. PubMed ID: 7516641
[TBL] [Abstract][Full Text] [Related]
33. [Nonspecific cell-mediated immunity of gynecologic cancer patients and related effects of chemotherapy and immunotherapy].
Takada M
Gan To Kagaku Ryoho; 1983 Jun; 10(6):1480-5. PubMed ID: 6409005
[TBL] [Abstract][Full Text] [Related]
34. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ
Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564
[TBL] [Abstract][Full Text] [Related]
35. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
36. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD
Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
[TBL] [Abstract][Full Text] [Related]
37. Impact of adjuvant chemo- and radiotherapy on the cellular immune system of breast cancer patients.
Mellios T; Ko HL; Beuth J
In Vivo; 2010; 24(2):227-30. PubMed ID: 20364000
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory therapy with thymopentin and indomethacin. Successful restoration of interleukin-2 synthesis in patients undergoing major surgery.
Faist E; Markewitz A; Fuchs D; Lang S; Zarius S; Schildberg FW; Wachter H; Reichart B
Ann Surg; 1991 Sep; 214(3):264-73; discussion 274-5. PubMed ID: 1929608
[TBL] [Abstract][Full Text] [Related]
39. Cell-mediated immunity and blocking factor in ovarian carcinoma.
Mitchell MS; Kohorn EI
Obstet Gynecol; 1976 Nov; 48(5):590-7. PubMed ID: 980285
[TBL] [Abstract][Full Text] [Related]
40. Cell-mediated immunity and serum blocking factors in cancer patients during chemotherapy and immunotherapy.
Noonan FP; Halliday WJ; Wall DR; Clunie GJ
Cancer Res; 1977 Aug; 37(8 Pt 1):2473-80. PubMed ID: 872076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
